Consolidated Statement Of Cash Flows

ROHTO PHARMACEUTICAL CO.,LTD. - Filing #7295708

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
18,589,000,000 JPY
12,901,000,000 JPY
Interest and dividends received
1,293,000,000 JPY
992,000,000 JPY
Income taxes paid
-5,785,000,000 JPY
-5,011,000,000 JPY
Interest paid
-94,000,000 JPY
-108,000,000 JPY
Net cash provided by (used in) operating activities
14,007,000,000 JPY
8,811,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-5,025,000,000 JPY
-3,906,000,000 JPY
Proceeds from sale of property, plant and equipment
5,000,000 JPY
138,000,000 JPY
Net cash provided by (used in) investing activities
-83,525,000,000 JPY
-8,351,000,000 JPY
Purchase of investment securities
-3,821,000,000 JPY
-3,605,000,000 JPY
Purchase of shares of subsidiaries resulting in change in scope of consolidation
-74,479,000,000 JPY
JPY
Cash flows from financing activities
Dividends paid
-3,422,000,000 JPY
-2,737,000,000 JPY
Proceeds from long-term borrowings
14,977,000,000 JPY
JPY
Repayments of long-term borrowings
-1,979,000,000 JPY
-1,740,000,000 JPY
Purchase of shares of subsidiaries not resulting in change in scope of consolidation
-13,505,000,000 JPY
JPY
Net cash provided by (used in) financing activities
40,297,000,000 JPY
-4,902,000,000 JPY
Other, net
-428,000,000 JPY
-454,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
3,937,000,000 JPY
3,698,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-25,283,000,000 JPY
-744,000,000 JPY
Cash and cash equivalents
61,278,000,000 JPY
86,562,000,000 JPY
76,970,000,000 JPY
77,691,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.